報價延遲最少15分鐘:2024/12/24 12:22 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.015 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.78/0.81
|
|
企業價值
2.90B
|
| 資產負債 |
|
每股賬面淨值
3.47
|
| 現金流量 |
|
現金流量率
0.07
|
| 損益表 |
|
收益
726.44M
|
|
每股收益
3.80
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:22 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. |